Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000176238 | SCV000227856 | uncertain significance | not provided | 2015-06-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000176238 | SCV001820197 | uncertain significance | not provided | 2020-05-21 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000176238 | SCV002355284 | likely benign | not provided | 2024-10-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002516703 | SCV003726498 | uncertain significance | Inborn genetic diseases | 2024-05-30 | criteria provided, single submitter | clinical testing | The c.3631C>T (p.P1211S) alteration is located in exon 21 (coding exon 19) of the FREM1 gene. This alteration results from a C to T substitution at nucleotide position 3631, causing the proline (P) at amino acid position 1211 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |